Black Diamond Therapeutics Inc (BDTX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.16x

Black Diamond Therapeutics Inc (BDTX) has a Cash Flow Reinvestment Rate of 0.16x as of March 2025, reinvesting $8.55 Million (capex $0.00 plus investments $8.55 Million) from operating cash flow of $53.41 Million. See BDTX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.16x
(Capex + Investments) / Operating CF

Total Reinvested

$8.55 Million
Capex + Investments

Operating Cash Flow

$53.41 Million
USD

Capital Expenditures

$0.00
USD

Black Diamond Therapeutics Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for Black Diamond Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see Black Diamond Therapeutics Inc cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Black Diamond Therapeutics Inc (2025–2025)

Year-by-year capital reinvestment analysis for Black Diamond Therapeutics Inc. See financial flexibility index of Black Diamond Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 1.52x $44.93 Million $29.61 Million $0.00
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow